The BWEL randomized controlled trial (n=542, Stage 2-3 patients) delivered 42 coach calls over two years and produced clinically meaningful six-month improvements in physical function, fatigue, and social engagement—outcomes that directly support better chemotherapy tolerance through lowered systemic inflammation and improved metabolic control. This structured intervention corrects a long-standing gap: prior observational data linked post-diagnosis weight loss to 10-15% lower recurrence risk (e.g., 2022 meta-analysis in Journal of Clinical Oncology, 12 cohorts, 22,000 women), yet oncology practices offered no scalable delivery model until BWEL. The trial’s multi-center design across 635 sites strengthens external validity beyond single-institution reports, though two-year survival endpoints remain pending and industry funding disclosures are absent. A key missed angle is estrogen suppression: adipose tissue aromatization drives recurrence in ER+ disease, and the observed 5-7% weight drop likely reduces circulating estradiol faster than diet advice alone, echoing findings from the 2019 ENERGY trial (RCT, n=692). Implementation barriers such as rural broadband access and coach training costs are not addressed in the ASCO abstract, limiting immediate rollout.